Renal effects of chronic pharmacological manipulation of CB2 receptors in rats with diet-induced obesity

British Journal of Pharmacology

Volumn 173, Issue 7, 2016, Pages 1128-1142

  Jenkin, K A ^a   O'Keefe, L ^a   Simcocks, A C ^a   Briffa, J F ^b   Mathai, M L ^a,c   McAinch, A J ^a   Hryciw, Deanne H ^b  

^a VICTORIA UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; CANNABINOID; CANNABINOID 2 RECEPTOR; CYTOKINE; FAT INTAKE; INDOLE DERIVATIVE; IODOPRAVADOLINE;

ADMINISTRATION AND DOSAGE; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FAT INTAKE; FIBROSIS; GLOMERULUS; KIDNEY; KIDNEY TUBULE; MALE; METABOLISM; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; WEIGHT GAIN;

ANIMALS; CANNABINOIDS; CYTOKINES; DIETARY FATS; FIBROSIS; INDOLES; KIDNEY; KIDNEY GLOMERULUS; KIDNEY TUBULES; MALE; OBESITY; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB2; WEIGHT GAIN;

EID: 84929646402     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13056     Document Type: Article

References (73)

1. Abassi Z, Winaver J, Feuerstein GZ, (2009). The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality. Biochem Pharmacol 78: 933-940.
2. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. (2013). Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 24: 302-308.
3. Agudo J, Martin M, Roca C, Molas M, Bura AS, Zimmer A, et al. (2010). Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia 53: 2629-2640.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
5. Amazonas RB, Lopes de Faria JB, (2006). Effects of tight blood pressure control on glomerular hypertrophy in a model of genetic hypertension and experimental diabetes mellitus. Life Sci 79: 2135-2143.
6. Barutta F, Piscitelli F, Pinach S, Bruno G, Gambino R, Rastaldi MP, et al. (2011). Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes 60: 2386-2396.
7. Booth KM, Pinkston MM, Poston WS, (2005). Obesity and the built environment. J Am Diet Assoc 105: S110-S117.
8. Branton MH, Kopp JB, (1999). TGF-β and fibrosis. Microbes Infect 1: 1349-1365.
9. Briffa JF, McAinch AJ, Poronnik P, Hryciw DH, (2013). Adipokines as a link between obesity and chronic kidney disease. Am J Physiol Renal Physiol 305: F1629-F1636.
10. Cabral GA, Griffin-Thomas L, (2009). Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med 11: e3.
11. Cha DR, Kim NH, Yoon JW, Jo SK, Cho WY, Kim HK, et al. (2000). Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl 77: S104-S112.
12. Cignarelli M, Lamacchia O, (2007). Obesity and kidney disease. Nutr Metab Cardiovasc Dis 17: 757-762.
13. Cornall LM, Mathai ML, Hryciw DH, McAinch AJ, (2011). Diet-induced obesity up-regulates the abundance of GPR43 and GPR120 in a tissue specific manner. Cell Physiol Biochem 28: 949-958.
14. Curto-Reyes V, Llames S, Hidalgo A, Menendez L, Baamonde A, (2010). Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. Br J Pharmacol 160: 561-573.
15. Decleves AE, Mathew AV, Cunard R, Sharma K, (2011). AMPK mediates the initiation of kidney disease induced by a high-fat diet. J Am Soc Nephrol 22: 1846-1855.
16. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, et al. (1997). Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 100: 1538-1546.
17. Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, Manin S, et al. (2009). Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS ONE 4: e5844.
18. Di Marzo V, (2008). The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 51: 1356-1367.
19. Dobrian AD, Davies MJ, Prewitt RL, Lauterio TJ, (2000). Development of hypertension in a rat model of diet-induced obesity. Hypertension 35: 1009-1015.
20. Eknoyan G, (2007). Obesity, diabetes, and chronic kidney disease. Curr Diab Rep 7: 449-453.
21. Gardner B, Zu LX, Sharma S, Liu Q, Makriyannis A, Tashkin DP, et al. (2002). Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-β. Biochem Biophys Res Commun 290: 91-96.
22. Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M, (2006). The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 69: 471-478.
23. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. (1999). HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A 96: 14228-14233.
24. He J, Whelton PK, (1999). Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 138: 211-219.
25. Hryciw DH, Lee EM, Pollock CA, Poronnik P, (2004). Molecular changes in proximal tubule function in diabetes mellitus. Clin Exp Pharmacol Physiol 31: 372-379.
26. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, et al. (2003). Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A 100: 10529-10533.
27. Idris AI, Sophocleous A, Landao-Bassonga E, van't Hof RJ, Ralston SH, (2008). Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology 149: 5619-5626.
28. Janiak P, Poirier B, Bidouard JP, Cadrouvele C, Pierre F, Gouraud L, et al. (2007). Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int 72: 1345-1357.
29. Jayasooriya AP, Mathai ML, Walker LL, Begg DP, Denton DA, Cameron-Smith D, et al. (2008). Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci U S A 105: 6531-6536.
30. Jenkin KA, McAinch AJ, Grinfeld E, Hryciw DH, (2010). Role for cannabinoid receptors in human proximal tubular hypertrophy. Cell Physiol Biochem 26: 879-886.
31. Jenkin KA, Verty AN, McAinch AJ, Hryciw DH, (2012). Endocannabinoids and the renal proximal tubule: an emerging role in diabetic nephropathy. Int J Biochem Cell Biol 44: 2028-2031.
32. Jenkin KA, McAinch AJ, Briffa JF, Zhang Y, Kelly DJ, Pollock CA, et al. (2013). Cannabinoid receptor 2 expression in human proximal tubule cells is regulated by albumin independent of ERK1/2 signaling. Cell Physiol Biochem 32: 1309-1319.
33. de Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL, (2002). Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 26: S21-S24.
34. Kanellis J, Paizis K, Cox AJ, Stacker SA, Gilbert RE, Cooper ME, et al. (2002). Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. Kidney Int 61: 1696-1706.
35. Keenan KP, Coleman JB, McCoy CL, Hoe CM, Soper KA, Laroque P, (2000). Chronic nephropathy in ad libitum overfed Sprague-Dawley rats and its early attenuation by increasing degrees of dietary (caloric) restriction to control growth. Toxicol Pathol 28: 788-798.
36. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
37. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, et al. (2003). The cannabinoid system and immune modulation. J Leukoc Biol 74: 486-496.
38. Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D, (2005). Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am J Kidney Dis 46: 587-594.
39. LaBuda CJ, Koblish M, Little PJ, (2005). Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur J Pharmacol 527: 172-174.
40. Le Floch JP, Escuyer P, Baudin E, Baudon D, Perlemuter L, (1990). Blood glucose area under the curve. Methodological aspects. Diabetes Care 13: 172-175.
41. Levin BE, Dunn-Meynell AA, Balkan B, Keesey RE, (1997). Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats. Am J Physiol 273: R725-R730.
42. Liu Y, (2011). Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 7: 684-696.
43. Mathew AV, Okada S, Sharma K, (2011). Obesity related kidney disease. Curr Diabetes Rev 7: 41-49.
44. Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA, Di Marzo V, (2008). Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Mol Cell Endocrinol 286: S66-S78.
45. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
46. Muccioli GG, (2010). Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov Today 15: 474-483.
47. Mukherjee S, Adams M, Whiteaker K, Daza A, Kage K, Cassar S, et al. (2004). Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. Eur J Pharmacol 505: 1-9.
48. Mukhopadhyay P, Rajesh M, Pan H, Patel V, Mukhopadhyay B, Batkai S, et al. (2010). Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med 48: 457-467.
49. Munoz-Luque J, Ros J, Fernandez-Varo G, Tugues S, Morales-Ruiz M, Alvarez CE, et al. (2008). Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 324: 475-483.
50. Nam DH, Lee MH, Kim JE, Song HK, Kang YS, Lee JE, et al. (2012). Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. Endocrinology 153: 1387-1396.
51. Onaivi ES, Carpio O, Ishiguro H, Schanz N, Uhl GR, Benno R, (2008). Behavioral effects of CB2 cannabinoid receptor activation and its influence on food and alcohol consumption. Ann N Y Acad Sci 1139: 426-433.
52. Pacher P, Mechoulam R, (2011). Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50: 193-211.
53. Pacher P, Batkai S, Kunos G, (2005). Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology 48: 1130-1138.
54. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-106.
55. Pinhal CS, Lopes A, Torres DB, Felisbino SL, Rocha Gontijo JA, Boer PA, (2013). Time-course morphological and functional disorders of the kidney induced by long-term high-fat diet intake in female rats. Nephrol Dial Transplant 28: 2464-2476.
56. Qi W, Chen X, Holian J, Mreich E, Twigg S, Gilbert RE, et al. (2006). Transforming growth factor-β1 differentially mediates fibronectin and inflammatory cytokine expression in kidney tubular cells. Am J Physiol Renal Physiol 291: F1070-F1077.
57. Qi W, Chen X, Poronnik P, Pollock CA, (2008). Transforming growth factor-β/connective tissue growth factor axis in the kidney. Int J Biochem Cell Biol 40: 9-13.
58. Romero-Zerbo SY, Garcia-Gutierrez MS, Suarez J, Rivera P, Ruz-Maldonado I, Vida M, et al. (2012). Overexpression of cannabinoid CB2 receptor in the brain induces hyperglycaemia and a lean phenotype in adult mice. J Neuroendocrinol 24: 1106-1119.
59. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A, (2008). SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 31: 2169-2176.
60. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, et al. (1999). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126: 665-672.
61. Servettaz A, Kavian N, Nicco C, Deveaux V, Chereau C, Wang A, et al. (2010). Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am J Pathol 177: 187-196.
62. Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL, (2007). The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 101: 87-98.
63. Ting C-H, Chi C-W, Li C-P, Chen C-Y, (2015). Differential modulation of endogenous cannabinoid CB1 and CB2 receptors in spontaneous and splice variants of ghrelin-induced food intake in conscious rats. Nutrition 31: 230-235.
64. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365: 1389-1397.
65. Wang J, Ueda N, (2009). Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat 89: 112-119.
66. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ, (2008). Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 73: 19-33.
67. Wohlfarth V, Drumm K, Mildenberger S, Freudinger R, Gekle M, (2003). Protein uptake disturbs collagen homeostasis in proximal tubule-derived cells. Kidney Int Suppl: S103-S109.
68. Wolf G, Hamann A, Han DC, Helmchen U, Thaiss F, Ziyadeh FN, et al. (1999). Leptin stimulates proliferation and TGF-β expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int 56: 860-872.
69. Wolf G, Chen S, Han DC, Ziyadeh FN, (2002). Leptin and renal disease. Am J Kidney Dis 39: 1-11.
70. World Health Organization (2013). Obesity and overweight factsheet [online]. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/ (accessed 2/12/2013).
71. Wright JA, Cavanaugh KL, (2010). Dietary sodium in chronic kidney disease: a comprehensive approach. Semin Dial 23: 415-421.
72. Xia X, Yan J, Shen Y, Tang K, Yin J, Zhang Y, et al. (2011). Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS ONE 6: e16556.
73. Ziyadeh FN, (2008). Different roles for TGF-β and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy. Diabetes Res Clin Pract 82: S38-S41.